Walleye Trading LLC Akero Therapeutics, Inc. Call Options Transaction History

Walleye Trading LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$17.76 - $31.18 $42,624 - $74,832	-2,400 Reduced 9.8%	22,100 $558,000
Q4 2023 Feb 14, 2024	BUY	$11.38 - $50.33 $194,598 - $860,643	17,100 Added 231.08%	24,500 $572,000
Q3 2023 Nov 14, 2023	SELL	$41.19 - $52.25 $243,021 - $308,275	-5,900 Reduced 44.36%	7,400 $374,000
Q2 2023 Aug 14, 2023	SELL	$36.89 - $56.88 $988,652 - $1.52 Million	-26,800 Reduced 66.83%	13,300 $620,000
Q1 2023 May 15, 2023	BUY	$37.27 - $50.24 $864,664 - $1.17 Million	23,200 Added 137.28%	40,100 $1.53 Million
Q4 2022 Feb 14, 2023	SELL	$33.44 - $54.8 $632,016 - $1.04 Million	-18,900 Reduced 52.79%	16,900 $926,000
Q3 2022 Nov 14, 2022	BUY	$10.15 - $34.05 $363,370 - $1.22 Million	35,800 New	35,800 $1.22 Million

190

73.8M

241K

647K

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.49B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Trading LLC with notifications on news.